Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 5/20 | 0.42 |
| ▸ | BACE1 | P56817 | 8/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695562 | 0.92 | BACE1 (0.45) | ENPEPBACE1BACE2CTSD | |
| SCHEMBL29352968 | 0.88 | FOLH1 (0.41) | — | |
| SCHEMBL31332141 | 0.88 | FOLH1 (0.41) | — | |
| SCHEMBL31031450 | 0.87 | FURIN (0.48) | BACE1BACE2CTSD | |
| SCHEMBL29695558 | 0.87 | BACE1 (0.43) | BACE1BACE2CTSD | |
| SCHEMBL29351135 | 0.86 | GNPAT (0.45) | ENPEPBACE1KEAP1 | |
| SCHEMBL31400977 | 0.85 | NMT1 (0.47) | BACE1BACE2CTSD | |
| SCHEMBL29370769 | 0.84 | ENPEP (0.46) | ENPEPBACE1BACE2CTSD | |
| SCHEMBL6856783 | 0.84 | NMT2 (0.46) | BACE1 | |
| SCHEMBL6856774 | 0.84 | NMT2 (0.46) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136555-A9 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | TUBB6, GALNT10, TUBB | ENPEP 153/4885BACE1 2881/4885BACE2 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.